EU/3/12/966

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

Oncology Ltd, United Kingdom, for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate for the treatment of soft tissue sarcoma.

In February 2013, Nexus Oncology Ltd changed name to Ockham Europe Limited.

The sponsorship was transferred to Merck KGaA, Germany, in March 2015.

Key facts

Active substance
(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate
Disease / condition
Treatment of soft-tissue sarcoma
Date of decision
05/03/2012
Outcome
Withdrawn
Orphan decision number
EU/3/12/966

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

Sponsor's contact details

Merck KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
Tel. +49 6151 72 32 80
Fax +49 6151 72 20 00
E-mail: service@merck.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating